Atara, Pierre Fabre's cell therapy to get another shot at FDA approval

Max Gelman / endpoints - There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an approval, Atara said ...

AI Summary: Regulators have agreed to re-examine a previously rejected cell‑therapy application for a rare lymphoma, giving the Atara‑Pierre Fabre program another opportunity at approval. The decision follows additional data and stakeholder engagement, offering the developer a second bite at the apple and patients a renewed, if cautious, hope for a novel treatment pathway.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 46 hrs

FDA advisory panel rejects camizestrant after SERENA‑6 results / 29 days

VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 15 days

New drug doubles one-year survival in metastatic pancreatic cancer / 6 wks

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 46 hrs

Common asthma drug may overcome immunotherapy resistance in cancers / 11 days

Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days